Related references
Note: Only part of the references are listed.Risk of Developing Hypokalemia in Patients With Hypertension Treated With Combination Antihypertensive Therapy
Maria Lukacs Krogager et al.
HYPERTENSION (2020)
Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure
Zachary L. Cox et al.
JACC-HEART FAILURE (2020)
Diuretic Therapy for Patients With Heart Failure JACC State-of-the-Art Review
G. Michael Felker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure
Christopher Stuart Wilcox et al.
HYPERTENSION (2020)
Furosemide and spironolactone doses and hyponatremia in patients with heart failure
Ivan Velat et al.
BMC PHARMACOLOGY & TOXICOLOGY (2020)
Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion
Jeffrey J. Liu et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats
Tyler C. Beck et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine
Shane W. Kaski et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials
Michael S. Kiernan et al.
JOURNAL OF CARDIAC FAILURE (2018)
Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor
Selena S. Schattauer et al.
CELLULAR SIGNALLING (2017)
Rationale and Design of the Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial: A Double-blind, Randomized, Placebo-Controlled Study to Determine the Effect of Combined Diuretic Therapy (Loop Diuretics With Thiazide-Type Diuretics) Among Patients With Decompensated Heart Failure
Joan Carles Trullas et al.
JOURNAL OF CARDIAC FAILURE (2016)
Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons
Jonathan M. Ehrich et al.
JOURNAL OF NEUROSCIENCE (2015)
Risk of Hyponatremia with Diuretics: Chlorthalidone versus Hydrochlorothiazide
Jan C. van Blijderveen et al.
AMERICAN JOURNAL OF MEDICINE (2014)
Thiazides and the risk of hypokalemia in the general population
Eline M. Rodenburg et al.
JOURNAL OF HYPERTENSION (2014)
Thiazide-Associated Hyponatremia: A Population-Based Study
Eline M. Rodenburg et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Microinjection of Glycine into the Hypothalamic Paraventricular Nucleus Produces Diuresis, Natriuresis, and Inhibition of Central Sympathetic Outflow
Zbigniew K. Krowicki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure
Jacob C. Jentzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study
Hiroo Kumagai et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A
S. Inan et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
Mechanisms involved in the hypotensive effect of a κ-opioid receptor agonist in hypertensive rats
Hai-Tao Guo et al.
ARCHIVES OF MEDICAL RESEARCH (2007)